Dr. Galen has been involved in instrumental research on the development of plasmid-based expression systems for delivery of foreign antigens from both prokaryotic and eukaryotic organisms.
He has invented two novel systems:
- Antigen transport system for export of antigens out to the surface of attenuated S. Typhi.
- Plasmid stabilization and selection system that removes the need for plasmid selection using antibiotics and guarantees plasmid retention in vivo after introduction into live vector strains.
Dr. Galen's work has resulted in multiple patents issued in both the United States and abroad.
Recent efforts have focused on the design and development of novel vaccines and therapeutic treatments against enteric disease caused by Clostridium difficile. On the vaccine side, Dr. Galen has worked on the development of a live oral vaccine designed to elicit toxin neutralizing antibodies against the three known toxins of C. difficile: Toxin A (TcdA), toxin B (TcdB), and binary toxin (CDT). On the therapeutic treatment side, he is collaborating on a unique project to engineer a probiotic strain of yeast called Saccharomyces boulardii to efficiently and stably deliver in situ therapeutically relevant levels of a novel tetravalent neutralizing antibody against CDI enterotoxins TcdA and TcdB, to interrupt recurrent disease.